Soolantra worth $87m in the last year

Written by on July 18, 2017 in patents, Soolantra (Ivermectin Cream 1%) with 0 Comments


One thing we have learned from the news that Perrigo and Galderma are embarking on a patent dispute, is how successful Soolantra has been as a product.

Perrigo Confirms Patent Challenge For Generic Version Of Soolantra Cream, 1%

Soolantra (ivermectin) cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. Annual market sales for the 12 months ending May 2017 were $87 million.

So sales of Soolantra are already approaching $100m a year.

[Update January 2018:] We now know that Soolantra has a $120m a year run rate from a further press release from Perrigo.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.